Paul Zeun

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/703621/paul-zeun-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

156 papers	7,302 citations	37 h-index	83 g-index
173 ext. papers	9,130 ext. citations	8 avg, IF	5.98 L-index

#	Paper	IF	Citations
156	Timing of selective basal ganglia white matter loss in premanifest Huntington's disease.. *NeuroImage: Clinical*, **2022**, 33, 102927	5.3	1
155	Suppression of Somatic Expansion As a Novel Therapeutic Approach for Huntington Disease and Other Repeat Expansion Disorders **2022**, 1, 163-175		
154	CAG Somatic Instability in a Huntington Disease Expansion Carrier Presenting with a Progressive Supranuclear Palsy-like Phenotype.. *Movement Disorders*, **2022**,	7	0
153	A MDS Evidence-Based Review on Treatments for Huntington's Disease. *Movement Disorders*, **2021**,	7	4
152	Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease. *Neurology: Genetics*, **2021**, 7, e617	3.8	2
151	Imbalanced basal ganglia connectivity is associated with motor deficits and apathy in Huntington's disease. *Brain*, **2021**,	11.2	2
150	Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study. *EBioMedicine*, **2021**, 65, 103266	8.8	4
149	Expanding the Spectrum of Movement Disorders Associated With Hexanucleotide Expansions. *Neurology: Genetics*, **2021**, 7, e575	3.8	11
148	Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington's Disease. *Frontiers in Neurology*, **2021**, 12, 616272	4.1	1
147	Human Huntington's disease pluripotent stem cell-derived microglia develop normally but are abnormally hyper-reactive and release elevated levels of reactive oxygen species. *Journal of Neuroinflammation*, **2021**, 18, 94	10.1	4
146	Altered nuclear architecture in blood cells from Huntington's disease patients. *Neurological Sciences*, **2021**, 1	3.5	0
145	Tracking Huntington's Disease Progression Using Motor, Functional, Cognitive, and Imaging Markers. *Movement Disorders*, **2021**, 36, 2282-2292	7	0
144	Fronto-striatal circuits for cognitive flexibility in far from onset Huntington's disease: evidence from the Young Adult Study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 143-149	5.5	3
143	Genetic testing in dementia - utility and clinical strategies. *Nature Reviews Neurology*, **2021**, 17, 23-36	15	4
142	Reply to 'Topographical layer imaging as a tool to track neurodegenerative disease spread in M1'. *Nature Reviews Neuroscience*, **2021**, 22, 69	13.5	1
141	Dynamics of Cortical Degeneration Over a Decade in Huntington's Disease. *Biological Psychiatry*, **2021**, 89, 807-816	7.9	10
140	Relating quantitative 7T MRI across cortical depths to cytoarchitectonics, gene expression and connectomics. *Human Brain Mapping*, **2021**, 42, 4996-5009	5.9	5

139	A Multi-Study Model-Based Evaluation of the Sequence of Imaging and Clinical Biomarker Changes in Huntington's Disease. *Frontiers in Big Data*, **2021**, 4, 662200	2.8	1
138	FAN1 controls mismatch repair complex assembly via MLH1 retention to stabilize CAG repeat expansion in Huntington's disease. *Cell Reports*, **2021**, 36, 109649	10.6	8
137	Aberrant Striatal Value Representation in Huntington's Disease Gene Carriers 25 Years Before Onset. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, **2021**, 6, 910-918	3.4	1
136	Mislocalization of Nucleocytoplasmic Transport Proteins in Human Huntington's Disease PSC-Derived Striatal Neurons. *Frontiers in Cellular Neuroscience*, **2021**, 15, 742763	6.1	1
135	Polyglutamine diseases. *Current Opinion in Neurobiology*, **2021**, 72, 39-47	7.6	2
134	Composite UHDRS Correlates With Progression of Imaging Biomarkers in Huntington's Disease. *Movement Disorders*, **2021**, 36, 1259-1264	7	6
133	Disease Onset in Huntington's Disease: When Is the Conversion?. *Movement Disorders Clinical Practice*, **2021**, 8, 352-360	2.2	7
132	Longitudinal Structural MRI in Neurologically Healthy Adults. *Journal of Magnetic Resonance Imaging*, **2020**, 52, 1385-1399	5.6	2
131	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. *Lancet Neurology, The*, **2020**, 19, 502-512	24.1	56
130	The human motor cortex microcircuit: insights for neurodegenerative disease. *Nature Reviews Neuroscience*, **2020**, 21, 401-415	13.5	20
129	Antisense oligonucleotides for neurodegeneration. *Science*, **2020**, 367, 1428-1429	33.3	41
128	Subcellular Localization And Formation Of Huntingtin Aggregates Correlates With Symptom Onset And Progression In A Huntington'S Disease Model. *Brain Communications*, **2020**, 2, fcaa066	4.5	16
127	Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease. *Annals of Neurology*, **2020**, 87, 751-762	9.4	14
126	A small molecule kicks repeat expansion into reverse. *Nature Genetics*, **2020**, 52, 136-137	36.3	1
125	The Dementias Platform UK (DPUK) Data Portal. *European Journal of Epidemiology*, **2020**, 35, 601-611	12.1	23
124	Expression of mutant exon 1 huntingtin fragments in human neural stem cells and neurons causes inclusion formation and mitochondrial dysfunction. *FASEB Journal*, **2020**, 34, 8139-8154	0.9	12
123	Longitudinal expression changes are weak correlates of disease progression in Huntington's disease. *Brain Communications*, **2020**, 2, fcaa172	4.5	3
122	Characterizing White Matter in Huntington's Disease. *Movement Disorders Clinical Practice*, **2020**, 7, 52-60	2.2	6

121	Therapeutic Antisense Targeting of Huntingtin. *DNA and Cell Biology*, **2020**, 39, 154-158	3.6	11
120	Wild-type huntingtin regulates human macrophage function. *Scientific Reports*, **2020**, 10, 17269	4.9	4
119	Activity or connectivity? A randomized controlled feasibility study evaluating neurofeedback training in Huntington's disease. *Brain Communications*, **2020**, 2, fcaa049	4.5	4
118	A new family with GLRB-related hyperekplexia showing chorea in homo- and heterozygous variant carriers. *Parkinsonism and Related Disorders*, **2020**, 79, 97-99	3.6	2
117	9 Aberrant striatal value representation in Huntington disease gene carriers 25 years before onset. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, e4.1-e4	5.5	
116	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. *Science Translational Medicine*, **2020**, 12,	17.5	24
115	Diffusion imaging in Huntington's disease: comprehensive review. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**,	5.5	5
114	One decade ago, one decade ahead in huntington's disease. *Movement Disorders*, **2019**, 34, 1434-1439	7	6
113	Multimodal characterization of the visual network in Huntington's disease gene carriers. *Clinical Neurophysiology*, **2019**, 130, 2053-2059	4.3	
112	Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. *Movement Disorders Clinical Practice*, **2019**, 6, 541-546	2.2	30
111	Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington's disease by etanercept treatment. *Scientific Reports*, **2019**, 9, 7202	4.9	7
110	Targeting Huntingtin Expression in Patients with Huntington's Disease. *New England Journal of Medicine*, **2019**, 380, 2307-2316	59.2	319
109	Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease. *Neuron*, **2019**, 101, 801-819	13.9	102
108	Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?. *Movement Disorders*, **2019**, 34, 584-585	7	8
107	Combined cerebral atrophy score in Huntington's disease based on atlas-based MRI volumetry: Sample size calculations for clinical trials. *Parkinsonism and Related Disorders*, **2019**, 63, 179-184	3.6	7
106	Association of CAG Repeats With Long-term Progression in Huntington Disease. *JAMA Neurology*, **2019**, 76, 1375-1385	17.2	22
105	A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. *EBioMedicine*, **2019**, 48, 568-580	8.8	63
104	Apathy Associated With Impaired Recognition of Happy Facial Expressions in Huntington's Disease. *Journal of the International Neuropsychological Society*, **2019**, 25, 453-461	3.1	2

103	FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat. *Human Molecular Genetics*, **2019**, 28, 650-661	5.6	56
102	Natural biological variation of white matter microstructure is accentuated in Huntington's disease. *Human Brain Mapping*, **2018**, 39, 3516-3527	5.9	11
101	Predicting clinical diagnosis in Huntington's disease: An imaging polymarker. *Annals of Neurology*, **2018**, 83, 532-543	9.4	15
100	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. *Neurology*, **2018**, 90, e717-e723	6.5	42
99	Clinical Features of Huntington's Disease. *Advances in Experimental Medicine and Biology*, **2018**, 1049, 1-28	3.6	53
98	Stimulating neural plasticity with real-time fMRI neurofeedback in Huntington's disease: A proof of concept study. *Human Brain Mapping*, **2018**, 39, 1339-1353	5.9	24
97	Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease. *NeuroImage: Clinical*, **2018**, 17, 312-324	5.3	14
96	Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study. *NeuroImage: Clinical*, **2018**, 19, 66-70	5.3	9
95	Response to the letter to the editor by Reilmann et al referring to our article titled "Motor cortex synchronization influences the rhythm of motor performance in premanifest Huntington's disease". *Movement Disorders*, **2018**, 33, 1371	7	
94	In vivo characterization of white matter pathology in premanifest huntington's disease. *Annals of Neurology*, **2018**, 84, 497-504	9.4	29
93	In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington's disease. *Scientific Reports*, **2018**, 8, 11447	4.9	9
92	Overlap between age-at-onset and disease-progression determinants in Huntington disease. *Neurology*, **2018**, 90, e2099-e2106	6.5	22
91	Huntington disease. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2018**, 147, 255-278	3	37
90	Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntington's disease. *Neuropsychology*, **2018**, 32, 958-965	3.8	8
89	Brain Regions Showing White Matter Loss in Huntington's Disease Are Enriched for Synaptic and Metabolic Genes. *Biological Psychiatry*, **2018**, 83, 456-465	7.9	54
88	Working Memory-Related Effective Connectivity in Huntington's Disease Patients. *Frontiers in Neurology*, **2018**, 9, 370	4.1	4
87	Altered Intracortical T-Weighted/T-Weighted Ratio Signal in Huntington's Disease. *Frontiers in Neuroscience*, **2018**, 12, 805	5.1	8
86	Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly. *Drugs and Aging*, **2018**, 35, 959-971	4.7	17

85	Learning Subject-Specific Directed Acyclic Graphs With Mixed Effects Structural Equation Models From Observational Data. *Frontiers in Genetics*, **2018**, 9, 430	4.5	
84	Testing a longitudinal compensation model in premanifest Huntington's disease. *Brain*, **2018**, 141, 2156-2166	11.2	19
83	Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells. *Scientific Reports*, **2017**, 7, 46740	4.9	18
82	The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients. *Scientific Reports*, **2017**, 7, 1307	4.9	89
81	Validation of a prognostic index for Huntington's disease. *Movement Disorders*, **2017**, 32, 256-263	7	27
80	Age of onset in Huntington's disease is influenced by CAG repeat variations in other polyglutamine disease-associated genes. *Brain*, **2017**, 140, e42	11.2	7
79	KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E4676-E4685	11.5	65
78	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. *Lancet Neurology, The*, **2017**, 16, 601-609	24.1	172
77	Operationalizing compensation over time in neurodegenerative disease. *Brain*, **2017**, 140, 1158-1165	11.2	39
76	Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease. *Human Brain Mapping*, **2017**, 38, 2819-2829	5.9	17
75	DNA repair in the trinucleotide repeat disorders. *Lancet Neurology, The*, **2017**, 16, 88-96	24.1	56
74	Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice. *Scientific Reports*, **2017**, 7, 14275	4.9	11
73	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. *JAMA Neurology*, **2017**, 74, 1352-1360	17.2	10
72	Gene suppression approaches to neurodegeneration. *Alzheimer's Research and Therapy*, **2017**, 9, 82	9	30
71	Test-Retest Reliability of Measures Commonly Used to Measure Striatal Dysfunction across Multiple Testing Sessions: A Longitudinal Study. *Frontiers in Psychology*, **2017**, 8, 2363	3.4	6
70	Therapies targeting DNA and RNA in Huntington's disease. *Lancet Neurology, The*, **2017**, 16, 837-847	24.1	175
69	Design optimization for clinical trials in early-stage manifest Huntington's disease. *Movement Disorders*, **2017**, 32, 1610-1619	7	8
68	Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. *Neurology*, **2017**, 89, 2495-2502	6.5	57

67	Structural imaging in premanifest and manifest Huntington disease. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2017**, 144, 247-261	3	14
66	Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington's Disease. *Frontiers in Neurology*, **2017**, 8, 519	4.1	23
65	Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays. *PLoS ONE*, **2017**, 12, e0189891	3.7	9
64	Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. *Journal of Neurochemistry*, **2016**, 139, 22-5	6	37
63	Reply letter to Jinnah "Locus pocus" and Albanese "Complex dystonia is not a category in the new 2013 consensus classification": Necessary evolution, no magic!. *Movement Disorders*, **2016**, 31, 1760-1762	7	1
62	George Huntington: a legacy of inquiry, empathy and hope. *Brain*, **2016**, 139, 2326-33	11.2	20
61	D20 Operationalising compensation over time in neurodegenerative disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A41.2-A41	5.5	
60	D4 Prediction of huntington disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A35.1-A35	5.5	
59	D8 Tms-eeg markers of inhibitory deficits in huntington disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A36.2-A36	5.5	
58	D22 Compensation in preclinical huntington disease: evidence from the track-on HD study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A42.2-A42	5.5	
57	Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease. *Journal of the International Neuropsychological Society*, **2016**, 22, 595-608	3.1	33
56	RNA-Seq of Huntington's disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. *Human Molecular Genetics*, **2016**, 25, 2893-2904	5.6	33
55	Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin-proteasome system. *Acta Neuropathologica*, **2016**, 131, 411-25	14.3	44
54	Disruption of immune cell function by mutant huntingtin in Huntington's disease pathogenesis. *Current Opinion in Pharmacology*, **2016**, 26, 33-8	5.1	26
53	Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance. *PLOS Currents*, **2016**, 8,		4
52	A Computational Cognitive Biomarker for Early-Stage Huntington's Disease. *PLoS ONE*, **2016**, 11, e0148409	3.7	27
51	Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease. *PLoS ONE*, **2016**, 11, e0163479	3.7	35
50	D16 White matter microstructure and natural biological variation in huntington disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A39.2-A39	5.5	

49	K4 The cost and value of a huntington disease multidisciplinary team meeting. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A80.2-A80	5.5	
48	D21 Longitudinal compensation in the cognitive network in huntington disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A42.1-A42	5.5	
47	Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. *Movement Disorders*, **2016**, 31, 436-57	7	148
46	B48 DNA repair pathways as a common genetic mechanism modulating the age at onset in polyglutamine diseases. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, A26.1-A26	5.5	
45	Incidence of adult Huntington's disease in the UK: a UK-based primary care study and a systematic review. *BMJ Open*, **2016**, 6, e009070	3	36
44	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. *Journal of the Neurological Sciences*, **2016**, 368, 243-8	3.2	32
43	Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease. *Human Brain Mapping*, **2016**, 37, 4615-4628	5.9	15
42	DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. *Annals of Neurology*, **2016**, 79, 983-90	9.4	135
41	Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. *Journal of Neurochemistry*, **2016**, 137, 782-94	6	26
40	Large-scale brain network abnormalities in Huntington's disease revealed by structural covariance. *Human Brain Mapping*, **2016**, 37, 67-80	5.9	13
39	A SNP in the HTT promoter alters NF-B binding and is a bidirectional genetic modifier of Huntington disease. *Nature Neuroscience*, **2015**, 18, 807-16	25.5	70
38	Huntington disease. *Nature Reviews Disease Primers*, **2015**, 1, 15005	51.1	672
37	Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. *Neurobiology of Disease*, **2015**, 83, 115-21	7.5	87
36	Short-interval observational data to inform clinical trial design in Huntington's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 1291-8	5.5	17
35	The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. *Neuropsychologia*, **2015**, 79, 138-46	3.2	42
34	Analysis of White Adipose Tissue Gene Expression Reveals CREB1 Pathway Altered in Huntington's Disease. *Journal of Huntingtons Disease*, **2015**, 4, 371-82	1.9	8
33	Longitudinal Diffusion Tensor Imaging Shows Progressive Changes in White Matter in Huntington's Disease. *Journal of Huntingtons Disease*, **2015**, 4, 333-46	1.9	24
32	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. *EBioMedicine*, **2015**, 2, 1420-9	8.8	91

31	Neuropsychiatry and White Matter Microstructure in Huntington's Disease. *Journal of Huntington's Disease*, **2015**, 4, 239-49	1.9	27
30	Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling. *Frontiers in Human Neuroscience*, **2015**, 9, 634	3.3	5
29	Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. *Neurobiology of Disease*, **2015**, 73, 388-98	7.5	37
28	Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. *Brain*, **2015**, 138, 3016-29	11.2	71
27	Prion degradation pathways: Potential for therapeutic intervention. *Molecular and Cellular Neurosciences*, **2015**, 66, 12-20	4.8	29
26	Mutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington's Disease T Lymphocytes. *PLoS ONE*, **2015**, 10, e0141793	3.7	6
25	Huntington disease: natural history, biomarkers and prospects for therapeutics. *Nature Reviews Neurology*, **2014**, 10, 204-16	15	600
24	Task-specific training in Huntington disease: a randomized controlled feasibility trial. *Physical Therapy*, **2014**, 94, 1555-68	3.3	32
23	White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression. *Cortex*, **2014**, 52, 98-112	3.8	46
22	Inconsistent emotion recognition deficits across stimulus modalities in Huntington?s disease. *Neuropsychologia*, **2014**, 64, 99-104	3.2	13
21	Biomarker development for Huntington's disease. *Drug Discovery Today*, **2014**, 19, 972-9	8.8	16
20	Correction of inter-scanner and within-subject variance in structural MRI based automated diagnosing. *NeuroImage*, **2014**, 98, 405-15	7.9	29
19	Skeletal muscle atrophy in R6/2 mice - altered circulating skeletal muscle markers and gene expression profile changes. *Journal of Huntington's Disease*, **2014**, 3, 13-24	1.9	11
18	The potential of composite cognitive scores for tracking progression in Huntington's disease. *Journal of Huntington's Disease*, **2014**, 3, 197-207	1.9	8
17	Interregional compensatory mechanisms of motor functioning in progressing preclinical neurodegeneration. *NeuroImage*, **2013**, 75, 146-154	7.9	26
16	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. *Lancet Neurology, The*, **2013**, 12, 637-49	24.1	557
15	Corpus callosal atrophy in premanifest and early Huntington's disease. *Journal of Huntington's Disease*, **2013**, 2, 517-26	1.9	21
14	Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners. *Journal of Huntington's Disease*, **2013**, 2, 159-75	1.9	29

13	Reference genes selection for transcriptional profiling in blood of HD patients and R6/2 mice. *Journal of Huntington's Disease*, **2013**, 2, 185-200	1.9	8
12	A critical evaluation of inflammatory markers in Huntington's Disease plasma. *Journal of Huntington's Disease*, **2013**, 2, 125-34	1.9	19
11	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. *Lancet Neurology, The*, **2012**, 11, 42-53	24.1	392
10	Emotion recognition in Huntington's disease: a systematic review. *Neuroscience and Biobehavioral Reviews*, **2012**, 36, 237-53	9	75
9	Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease. *Journal of Huntington's Disease*, **2012**, 1, 97-106	1.9	10
8	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. *Lancet Neurology, The*, **2011**, 10, 31-42	24.1	443
7	Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. *PLOS Currents*, **2010**, 2,		64
6	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. *Lancet Neurology, The*, **2009**, 8, 791-801	24.1	721
5	The application of NMR-based metabonomics in neurological disorders. *Neurotherapeutics*, **2006**, 3, 358-372	6.4	
4	Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. *Human Molecular Genetics*, **2000**, 9, 2683-9	5.6	166
3	Opportunity cost determines free-operant action initiation latency and predicts apathy. *Psychological Medicine*,1-10	6.9	
2	Timing of selective basal ganglia white matter loss in Huntington disease		1
1	Huntington Disease Integrated Staging System (HD-ISS): A Novel Evidence-Based Classification System For Staging		1